Blog

#ag-case-post a:hover{color:#0b6ea3 !important;} #ag-case-post .ag-pill:hover{background:#1f9ed6 !important;color:#ffffff !important;} #ag-case-post .ag-prod:hover{box-shadow:0 8px 22px rgba(26,47,69,.14) !important;} #ag-case-post .ag-btn:hover{opacity:.92 !important;} QUICK ANSWER A researcher ran a competitive 2,3-bisphosphoglycerate (2,3-BPG) ELISA on red blood cell (RBC) lysate. The standard curve was textbook, yet every lysate sample read at the top of the curve with no dose-response, and the most concentrated sample gave a negative absorbance. The kit was working — the sample matrix was not. RBC lysate carries endogenous peroxidase activity that reacts …

#ag-case-post a:hover{color:#0a6ea3;} #ag-case-post .ag-pill:hover{background:#1f9ed6;color:#ffffff;} #ag-case-post .ag-prod:hover{box-shadow:0 6px 18px rgba(31,158,214,0.22);} #ag-case-post .ag-cta-btn:hover{opacity:0.92;} Quick answer A competitive ELISA is running correctly when the blank (zero standard) gives the highest OD, the standard curve drops smoothly with rising concentration, and your samples land in the middle of that curve. If your interpolated values already sit comfortably inside the kit's range — for the Bovine PGE2 (PGE2) ELISA that is 15.6–1000 pg/mL — you generally do not need to dilute. Fit the standards with a 4-parameter logistic (4PL) regr …

QUICK ANSWER If your ELISA returns sample concentrations that are orders of magnitude too high, the assay itself is usually fine — the error is almost always in data analysis. The most common culprit is entering the wrong standard concentrations when building the standard curve. In a recent porcine MAP (PigMAP) sandwich ELISA case, a researcher assigned a 5000–78 ng/mL range to standards that should have been 10–0.156 ng/mL. The optical density (OD) readings were valid; only the concentrations tied to them were wrong. Re-assigning the correct values to the same ODs brought results back into a sensible range. On this page The problem Snapshot of t …

Quick answer On the GDF-6 (Growth Differentiation Factor 6) ELISA Kit, a researcher saw an elevated blank (OD ≈ 0.41) with the two lowest standards reading at or below it, and no signal for a recombinant GDF-6 sample. The cause was a background/handling issue — most likely an over-concentrated HRP conjugate, incomplete washing, or stale wash buffer — not a fault in the antigen or kit. Fresh reagents, thorough washing, and a rebuilt low-end curve resolve it. On this page Click any section below to jump straight to it ↓ The problem › Snapshot of the data › Why it happens › Our a …

Announcement · Powered by Assay GenieIntroducing BioSymposia: The Gathering Place for ScienceWe’re excited to announce the launch of BioSymposia, our new sister platform and a free home for scientific events. BioSymposia helps researchers discover conferences, symposia and workshops across every discipline — and helps organisers put their events in front of a global research community.Explore BioSymposia →96+events listed25+scientific disciplines80+countries coveredFreeto list your eventKey TakeawaysBioSymposia is Assay Genie’s new sister site: a free platform for discovering scientific events worldwide.Browse conferences, symposia and workshops across 25+ disciplines in 80+ coun …

Written by Seán Mac Fhearraigh, PhD  •  Updated: 19 May 2026  •  ~9 min read Quick Answer ELISA and Western Blot are both antibody-based protein detection methods. ELISA is faster, higher throughput and gives you a precise quantitative number from complex samples. Western Blot separates proteins by size first, so it tells you whether your antibody is binding the right molecular weight band — making it the gold standard for protein identity confirmation. Use ELISA to measure how much; use Western Blot to confirm what. On this page ELISA vs Western Blot at a glance What is ELISA? What is Western Blot? Key differences in detail Sensitivity & quantitation Throug …

Written by Seán Mac Fhearraigh, PhD  •  Updated: 19 May 2026  •  ~9 min read Quick Answer The five main types of ELISA are sandwich, competitive, direct, indirect and multiplex. Sandwich ELISA is the most common — used for proteins and cytokines. Competitive ELISA suits small molecules like hormones. Indirect ELISA is the standard for antibody screening. Direct ELISA is the simplest format. Multiplex measures many analytes per well. On this page All ELISA types at a glance Sandwich ELISA Competitive ELISA Direct ELISA Indirect ELISA Multiplex ELISA Other formats (ELISpot, FluoroSpot, CLIA, cell-based) How to choose the right format Kit formats: pre-coated vs DIY …

Written by Seán Mac Fhearraigh, PhD  •  Updated: 19 May 2026  •  ~10 min read Quick Answer A sandwich ELISA uses two antibodies — a capture antibody immobilised on a 96-well plate and an enzyme-linked detection antibody — to bind two different epitopes on the same target protein. Signal is directly proportional to analyte concentration. A typical sandwich ELISA takes 3–4 hours and detects analyte at pg/mL to ng/mL levels. On this page What is a sandwich ELISA? When to use a sandwich ELISA The principle in detail Pre-coated sandwich ELISA protocol DIY sandwich ELI …

The year 2026 has brought an unsettling spotlight onto an old adversary: Hantavirus. What began as isolated cases has rapidly escalated into a multi-country surge, leaving scientists and public health officials scrambling for answers. This isn't merely a resurgence; it's a stark warning, revealing how our planet's changing climate and dwindling biodiversity are directly fueling new patterns of disease emergence. Introduction Hantaviruses, a family of RNA viruses primarily transmitted to humans through contact with infected rodent excreta, have long posed a public health threat. However, the current global surge in Hantavirus infections is unprecedented, prompting urgent investigations into …

Hantavirus, a silent threat lurking in rodent populations, has long posed a significant public health challenge with its severe and often fatal outcomes. For decades, the quest for effective vaccines has been a scientific priority. Now, a new era of vaccine development is dawning, spearheaded by revolutionary mRNA technology, promising unprecedented speed and efficacy in our fight against this elusive pathogen. Introduction Orthohantaviruses, commonly known as hantaviruses, are a group of zoonotic viruses responsible for two severe human diseases: Hemorrhagic Fever with Renal Syndrome (HFRS) in Eurasia and Hantavirus Pulmonary Syndrome (HPS) in the Americas. These illnesses carry high fata …

As hantavirus cases continue to rise globally, the question becomes not just how to detect infections, but how to prevent them in the first place. Recent epidemiological investigations across California, Qingdao, and the China-Russia border reveal that hantavirus prevention is achievable through a combination of environmental management, public awareness, and targeted surveillance. This comprehensive approach—integrating rodent control, habitat modification, and early detection—offers hope in mitigating the burden of this deadly virus in our changing world. Introduction Hantavirus infections have plagued human populations for decades, yet remarkably, the majority of cases are preventable. …

Imagine a future where cancer cells, once masters of disguise, are forced to reveal themselves and even train the body's immune system to fight back. This isn't science fiction; it's the groundbreaking reality emerging from the latest advancements in cancer immunotherapy. Researchers are now exploring a revolutionary strategy: turning tumors against themselves by reprogramming their very cells into powerful immune sentinels. Introduction For decades, the fight against cancer has been a relentless pursuit, marked by both triumphs and formidable challenges. While traditional treatments like chemotherapy and radiation have saved countless lives, they often come with significant side effects an …

Imagine a world where cancer treatment is no longer a blunt instrument but a precision-guided surgical strike, executed by the body's own immune system. For years, we have dreamed of 'smart' cells that can navigate the complex terrain of a tumor, distinguish friend from foe with absolute certainty, and adapt their behavior in real-time. Today, that dream is rapidly becoming a reality through the emergence of Programmable Synthetic Hybrid Receptors, or Hybrid-Rs, which are redefining the very boundaries of immunotherapy. Introduction The landscape of modern oncology has been fundamentally altered by the advent of Chimeric Antigen Receptor (CAR) T-cell therapy. By genetically engineering a pa …

For years, our understanding of cancer focused primarily on the tumor cells themselves and the immune system's response. However, a groundbreaking wave of research is revealing a startling truth: nerves, long considered mere conduits for pain or sensation, are actively co-opted by cancer to build a formidable 'neural shield,' driving resistance to even our most advanced immunotherapies. This paradigm shift is reshaping how we view the battle against cancer. Introduction Immunotherapy has revolutionized cancer treatment, offering unprecedented hope for many patients by harnessing the body's own immune system to fight malignant cells. Yet, a significant challenge remains: a substantial portio …

Imagine a specialized squad of immune cells, meticulously trained and equipped, not just to fight cancer, but to sniff it out by its unique metabolic scent. This isn't science fiction; it's the groundbreaking reality emerging from cutting-edge immunology research. Scientists are now engineering these 'metabolic bloodhounds' to track down and eliminate tumors, offering a revolutionary new strategy in the relentless battle against cancer. Introduction For decades, the fight against cancer has been a complex dance between aggressive treatments and the elusive nature of tumor cells. While immunotherapies like CAR-T cell therapy have revolutionized the treatment of hematological malignancies, so …

Imagine a future where the devastating impact of a stroke could be significantly mitigated, not just by managing symptoms, but by directly repairing the cellular machinery damaged during the event. This isn't science fiction; it's the rapidly evolving reality of mitochondrial transplantation, a groundbreaking approach poised to redefine how we restore neural function after ischemic stroke. Introduction Ischemic stroke, caused by a blockage in blood flow to the brain, deprives neurons of vital oxygen and nutrients, leading to rapid cellular damage and death. The aftermath can leave individuals with profound and lasting neurological deficits. For decades, treatments have focused on restoring …

For decades, the brain has been considered an immune sanctuary, protected by the formidable blood-brain barrier. This intricate defense system, while vital for safeguarding our most complex organ, has simultaneously posed an immense challenge for delivering therapeutic drugs to treat neurological diseases. But what if there was a hidden "backdoor," a previously overlooked pathway offering a direct route into the brain? Recent groundbreaking research suggests such a gateway exists, nestled within the very bones of our skull. Introduction The concept of the brain as an "immune-privileged" site has long dominated neuroscience, largely due to the blood-brain barrier (BBB) – a highly selective s …

For decades, the battle against cancer has focused on the cellular 'soldiers' and the genetic 'blueprints' within them. Yet, a vast, invisible world of communication exists between these cells—a secret language of proteins released into the extracellular space. These secreted molecules often hold the key to why some patients respond to immunotherapy while others do not, but until now, mapping this complex 'secretome' has been an insurmountable challenge for modern oncology. Introduction The landscape of cancer treatment was forever changed by the advent of immunotherapy, yet the 'holy grail' of precision medicine remains elusive: the ability to predict with certainty which patient will bene …

Imagine a future where chronic autoimmune diseases, once managed by powerful pharmaceuticals with challenging side effects, are instead calmed by a gentle electrical pulse. This isn't science fiction; it's the burgeoning reality of bioelectronic medicine, a revolutionary field poised to redefine how we approach conditions like rheumatoid arthritis and lupus. In 2026, the vagus nerve, a crucial highway between brain and body, is emerging as the unexpected hero in this therapeutic revolution. Introduction For decades, autoimmune diseases have presented a formidable challenge to medical science. Conditions where the body's immune system mistakenly attacks its own tissues, such as rheumatoid ar …

Imagine a future where cancer treatment isn't a grueling, months-long process involving cell extraction and reinfusion, but a simple, targeted injection that reprograms your body's own immune cells to fight disease from within. This isn't science fiction; it's the rapidly emerging reality of in vivo CAR-T engineering, a revolutionary approach poised to transform immunotherapy and bring 'off-the-shelf' treatments closer than ever before. Introduction Chimeric Antigen Receptor (CAR) T-cell therapy has already revolutionized the treatment landscape for certain blood cancers, offering a powerful new weapon against previously intractable diseases. However, the traditional 'ex vivo' manufacturing …

Imagine an elite squad of soldiers sent to neutralize a hidden fortress, only to find themselves wandering aimlessly in a thick, disorienting fog just outside the gates. This is the current reality for many immunotherapy treatments: powerful immune cells are engineered to kill cancer, yet they often fail to even find the tumor. However, a revolutionary new approach is turning these 'lost' cells into biological bloodhounds, capable of sniffing out a tumor's unique chemical scent to lead a precision strike. Introduction For decades, the 'holy grail' of oncology has been the development of therapies that can distinguish between healthy tissue and malignant growths with absolute precision. Whil …

Imagine a high-stakes game of hide-and-seek where the seeker is your immune system and the hider is a master of disguise: cancer. For decades, we believed the 'wanted' posters for tumor cells were limited to a few well-known mutations. However, a revolutionary field called immunopeptidomics is revealing that the surface of a cancer cell is actually covered in thousands of hidden messages, waiting to be decoded by the next generation of precision medicine. Introduction The human immune system relies on a sophisticated surveillance mechanism to distinguish 'self' from 'non-self.' At the heart of this process are Major Histocompatibility Complex (MHC) molecules, which act as cellular display c …

Imagine a world where we can fold the very fabric of life into microscopic machines, guiding the growth of a single neuron with the precision of a master architect. This isn't science fiction; it is the reality of DNA origami. By leveraging the natural base-pairing rules of genetic material, researchers are now building nanoscale scaffolds that don't just sit in the brain—they actively shape its development, offering a radical new blueprint for neuroregeneration and precision medicine. Introduction The human brain is perhaps the most complex structure in the known universe, a dense thicket of billions of neurons connected by trillions of synapses. For decades, our understanding of how this …

In the relentless fight against cancer, immunotherapy has emerged as a beacon of hope, harnessing the body's own defenses to combat malignant cells. Yet, predicting which patients will respond to these groundbreaking treatments remains a critical challenge. Recent scientific breakthroughs are now pointing towards an unexpected ally in this quest: IgG1 plasma cells, revealing their potential as a powerful new biomarker to forecast the success of cancer immunotherapy. Introduction Immunotherapy, particularly immune checkpoint blockade (ICB), has revolutionized cancer treatment, offering durable responses for many patients. However, a significant portion of individuals do not benefit, undersco …